Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P)
Eligible adults across New York may complete their evaluation through secure telehealth, with personalized treatment recommendations based on individual needs
Often considered as the more focused alternative to Melanotan II
Note that retinoids increase sun sensitivity, making sun protection especially important
Bernstein, H
Lancet Diabetes Endocrinol 2021;9:825-36.ArticlePubMed 129